Effect of Brivaracetam in Photosensitive Epileptic Subjects

Phase 2CompletedNCT00401648

UCB Pharma20 enrolled

Overview

to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Epilepsy

Interventions

BrivaracetamDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * epileptic subjects with generalized PPR Exclusion Criteria: * more than 2 concomitant antiepileptic drugs

Locations (5)

Unnamed facility

Marseille, France

Unnamed facility

Paris, France

Unnamed facility

Rouen, France

Unnamed facility

Strasbourg, France

Unnamed facility

Kork, Germany

Outcomes

Primary Outcomes

Identify lowest single oral dose producing maximal decrease or suppression of intermittent photic stimulation (IPS)photoparoxysmal response (PPR) in photosensitive epileptic subjects pre-dose

post placebo during 24h and post brivaracetam for up to 72 h

Secondary Outcomes

Assess relationship between plasma concentrations and changes in photosensitivity frequency range, time of onset and duration of suppressing effect

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.